TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26667790

Group type: EXPERIMENTAL
Intervention: Combined mediofrontal stimulation with double-cone-coil (2000 stimuli, 10 Hz) followed by left temporo-parietal stimulation with figure-of-eight-coil (2000 stimuli, 1 Hz)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Left dorsolateral-prefrontal-cortex stimulation with figure-of-eight-coil (2000 stimuli, 10 Hz) followed by temporo-parietal stimulation with figure-of-eight-coil (2000 stimuli, 1 Hz)
Number of subjects: 40
Study: 23339145

Group type: EXPERIMENTAL
Intervention: Nerve-sparing minilaparoscopic radical hysterectomy plus pelvic lymphadenectomy
Number of subjects: 87

Group type: COMPARATOR
Intervention: Conventional laparoscopic surgery
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Nerve-sparing minilaparoscopic radical hysterectomy
Number of subjects: 87

Group type: COMPARATOR
Intervention: Conventional laparoscopic surgery (last 10 procedures)
Number of subjects: 87
Study: 22034119

Group type: EXPERIMENTAL
Intervention: Tai chi exercise (n = 80), 18 40‐minute sessions over a 10‐week period delivered in a group format by a qualified instructor.
Number of subjects: 160

Group type: COMPARATOR
Intervention: Waitlist control group (n = 80), continued with their usual health care.
Number of subjects: 160
Study: 18714620

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional continuous intravenous infusion
Number of subjects: 60
Study: 16441475

Group type: EXPERIMENTAL
Intervention: Sodium phosphate (NaP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Polyethylene glycol-electrolyte solution (PEG-ELS)
Number of subjects: 100
Study: 12940870

Group type: EXPERIMENTAL
Intervention: Isoflavones from red clover (approximately 50 mg/day for 4 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 10741114

Group type: EXPERIMENTAL
Intervention: 100 ml of Iopamiron 300 mgI/ml (group 1)
Number of subjects: 87

Group type: COMPARATOR
Intervention: 2 ml/kg of Iopamiron 300 mgI/ml (group 2)
Number of subjects: 87
Study: 8885206

Group type: EXPERIMENTAL
Intervention: Protein‐sparing modified fast diet
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study: 1396619

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg daily
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Timolol 10 mg daily
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg daily
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 26
Study: 2865710

Group type: EXPERIMENTAL
Intervention: Levobunolol (0.5% and 1%) twice daily
Number of subjects: 391

Group type: COMPARATOR
Intervention: Timolol (0.5%) twice daily
Number of subjects: 391
Study: 29747594

Group type: EXPERIMENTAL
Intervention: Clinic referral / ongoing treatment (Treated Group)
Number of subjects: 79

Group type: COMPARATOR
Intervention: No Treatment (No Treatment Group)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Decoys (women without 'Booking GDM')
Number of subjects: 79
Study: 27173785

Group type: EXPERIMENTAL
Intervention: Pomalidomide plus low-dose dexamethasone (POM + LoDEX)
Number of subjects: 302
Study: 24943550

Group type: EXPERIMENTAL
Intervention: 12-week Mobile Application Programme (M.A.P.)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 22650123

Group type: EXPERIMENTAL
Intervention: Electroacupuncture and Tolterodine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (Pethidine and Anisodamine)
Number of subjects: 120
Study: 20736728

Group type: EXPERIMENTAL
Intervention: Pretest online discussion activity with a faculty e‐moderator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (students without access to the pretest online discussion)
Number of subjects: 0
Study: 18441454

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 16235460

Group type: EXPERIMENTAL
Intervention: 5 mg of hyperbaric bupivacaine combined with 2 mg of midazolam intrathecally (M+M)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 7.5 mg of hyperbaric bupivacaine (M)
Number of subjects: 60
Study: 14675879

Group type: EXPERIMENTAL
Intervention: Right atriotomy (Group 1)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Lateral cavatomy (Group 2)
Number of subjects: 27
Study: 10973391

Group type: EXPERIMENTAL
Intervention: Optimal values (cardiac index >4.5 L/min/m2, ratio of transcutaneous oxygen tension to fractional inspired oxygen >200, oxygen delivery index >600 mL/min/m2, and oxygen consumption index >170 mL/min/m2)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Normal values of systolic blood pressure, urine output, base deficit, hemoglobin, and cardiac index (control group)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both groups (optimal and control) who achieved optimal values
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both groups (optimal and control)
Number of subjects: 75
Study: 8993081

Group type: EXPERIMENTAL
Intervention: Fluoxetine; specific dosage and duration not mentioned
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo; specific dosage and duration not mentioned
Number of subjects: 0
Study: 1620908

Group type: EXPERIMENTAL
Intervention: Jet-induced airway vibration (10 Hz, 25 psi)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham pulsations (placebo treatment)
Number of subjects: 14
Study: 4022342

Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Number of subjects: 245
Study: 30409551

Group type: EXPERIMENTAL
Intervention: Higher anxiety symptoms (dichotomously assessed) in participants aged 65 years and older
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: Higher anxiety symptoms
Number of subjects: 918
Study: 27892594

Group type: EXPERIMENTAL
Intervention: Chloroprocaine 10 mg/ml (10 mg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Chloroprocaine 10 mg/ml (20 mg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Chloroprocaine 10 mg/ml (30 mg)
Number of subjects: 120
Study: 26614144

Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg kg(‐1) induction, 6‐10 mg kg(‐1)h(‐1) maintenance
Number of subjects: 30

Group type: COMPARATOR
Intervention: Midazolam 0.5 mg kg(‐1) induction, 0.5 mg kg(‐1) maintenance
Number of subjects: 30
Study: 22818226

Group type: EXPERIMENTAL
Intervention: Suicide care education programme (2-hour duration)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no education programme)
Number of subjects: 61
Study: 22185846

Group type: EXPERIMENTAL
Intervention: Hibiscus sabadariffa extract (SHE) standardized 10 mg of anthocyanins
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Hibiscus sabadariffa extract (SHE) standardized 20 mg of anthocyanins for 12 weeks
Number of subjects: 104

Group type: COMPARATOR
Intervention: Pravastatin 20 mg
Number of subjects: 104
Study: 19369457

Group type: EXPERIMENTAL
Intervention: Etoricoxib or Indomethacin for 7 days
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Chronic Allopurinol users
Number of subjects: 339

Group type: COMPARATOR
Intervention: Non-users of Allopurinol
Number of subjects: 339
Study: 17119520

Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 24
Study: 15094256

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: EPDS score >9 at week 4 postpartum
Number of subjects: 50
Study: 11510804

Group type: EXPERIMENTAL
Intervention: Keliximab 0.5 mg/kg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Keliximab 1.5 mg/kg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Keliximab 3.0 mg/kg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Keliximab (all doses combined)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 9764780

Group type: EXPERIMENTAL
Intervention: pVL nadir < or = 20 copies/ml
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: pVL nadir between 20 and 400 copies/ml
Number of subjects: 104

Group type: COMPARATOR
Intervention: pVL nadir > 400 copies/ml
Number of subjects: 104
Study: 7606150

Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: SUZI
Number of subjects: 72
Study: 3296353

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) treatment for 90 days followed by conversion to azathioprine and prednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy (AP) with azathioprine and prednisolone throughout
Number of subjects: 0
Study: 30573053

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with everolimus-eluting stents
Number of subjects: 1898

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1898
Study: 26198573

Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) program Respecting Choices® in addition to usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 23799692

Group type: EXPERIMENTAL
Intervention: Mailed low-literacy informational patient flyer
Number of subjects: 303

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 303
Study: 22248893

Group type: EXPERIMENTAL
Intervention: Caudal block
Number of subjects: 85

Group type: COMPARATOR
Intervention: Penile block
Number of subjects: 85
Study: 17935920

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of 1 ml methylprednisolone (40 mg/ml), 0.5 ml Lidocaine (5mg/ml), and 0.15 ml gadolinium (Omniscan 0.5 mmol/ml) into the wrist joint.
Number of subjects: 17
Study: 16551888

Group type: EXPERIMENTAL
Intervention: 4% succinylated gelatin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch
Number of subjects: 45

Group type: COMPARATOR
Intervention: 4% albumin
Number of subjects: 45
Study: 12765810

Group type: EXPERIMENTAL
Intervention: Mild hypothermia (rectal temperature 32.0 to 35.0 degrees C)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Control group (rectal temperature 36.5 to 37.0 degrees C)
Number of subjects: 396
Study: 10834773

Group type: EXPERIMENTAL
Intervention: Procaine (100 mg hyperbaric)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Lidocaine (50 mg hyperbaric)
Number of subjects: 70
Study: 9327671

Group type: EXPERIMENTAL
Intervention: Co-amoxiclav
Number of subjects: 619

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 619
Study: 8226001

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pindolol and Propranolol
Number of subjects: 19
Study: 3814678

Group type: EXPERIMENTAL
Intervention: Bilateral ECT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right unilateral ECT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ECT
Number of subjects: 0
Study: 29671079

Group type: EXPERIMENTAL
Intervention: Computer-based decision aid informing about PSA testing advantages and disadvantages
Number of subjects: 50000

Group type: EXPERIMENTAL
Intervention: Opportunistic screening
Number of subjects: 50000

Group type: COMPARATOR
Intervention: General practices
Number of subjects: 50000

Group type: COMPARATOR
Intervention: Urological practices
Number of subjects: 50000
Study: 27824753

Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg given 1 hour before IUD insertion
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg
Number of subjects: 118
Study: 24976224

Group type: EXPERIMENTAL
Intervention: Ketorolac (continuous infusion for 24 hours)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Normal saline (control, continuous infusion for 24 hours)
Number of subjects: 111
Study: 22313793

Group type: EXPERIMENTAL
Intervention: Fish oil (3 g/d) and kinako (29 g/d)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (usual diet)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Kinako (29 g/d)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Fish oil (3 g/d)
Number of subjects: 65
Study: 20886793

Group type: EXPERIMENTAL
Intervention: Sticking needle and traction method on three points of the mouth (Dicang, Kouheliao, Jiachengjiang)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Routine needling technique
Number of subjects: 101
Study: 18262705

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 62

Group type: COMPARATOR
Intervention: Venlafaxine
Number of subjects: 62
Study: 16871058

Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 16

Group type: COMPARATOR
Intervention: Patient-controlled analgesia with morphine (PCA)
Number of subjects: 16
Study: 14627879

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 10696629

Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids (5.4 g/d)
Number of subjects: 10

Group type: COMPARATOR
Intervention: sulfasalazine (2 g/d)
Number of subjects: 10
Study: 9356106

Group type: EXPERIMENTAL
Intervention: Epidural saline injection (10 mL) at L2‐3 or L3‐4 interspace 10 min after spinal anesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: No epidural saline injection (Control group)
Number of subjects: 20
Study: 8210973

Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Corn oil
Number of subjects: 29

Group type: COMPARATOR
Intervention: Cyclosporin
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (no oil supplementation)
Number of subjects: 29
Study: 2871010

Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate 5 mg every 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluphenazine 5 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haloperidol 20 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low doses of antipsychotic drugs
Number of subjects: 0
Study: 31847348

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) - intermittent use formulation (gum, sprays, inhaler)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electronic Nicotine Delivery Systems (ENDS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional tobacco smoking
Number of subjects: 0
Study: 28871428

Group type: EXPERIMENTAL
Intervention: Transanal Doppler-guided hemorrhoidal dearterialization with mucopexy (DM)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Hemorrhoidectomy using an ultrasonic scalpel (US)
Number of subjects: 44
Study: 24891337

Group type: EXPERIMENTAL
Intervention: FeNO treatment strategy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (symptoms-based management)
Number of subjects: 63
Study: 23243246

Group type: EXPERIMENTAL
Intervention: Pea protein isolates (PPI) included at 25% as the sole source of amino acids (AA)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Wheat-corn distillers dried grains with solubles (wcDDGS) included at 47.7% combined with 51% wheat
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Short-season corn included at 47.7% combined with 51% wheat
Number of subjects: 396

Group type: COMPARATOR
Intervention: Reference wheat included in all experiments
Number of subjects: 396
Study: 21276681

Group type: EXPERIMENTAL
Intervention: Endovascular repair (EVAR)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Open surgical repair (OSR)
Number of subjects: 299
Study: 19077924

Group type: EXPERIMENTAL
Intervention: Braced group
Number of subjects: 257

Group type: COMPARATOR
Intervention: Nonbraced group
Number of subjects: 257
Study: 16740530

Group type: EXPERIMENTAL
Intervention: Alternating pressure mattress
Number of subjects: 1972

Group type: COMPARATOR
Intervention: Alternating pressure overlay
Number of subjects: 1972
Study: 15546454

Group type: EXPERIMENTAL
Intervention: Chronic disease management programme (INT)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Conventional care (CON)
Number of subjects: 135
Study: 11522558

Group type: EXPERIMENTAL
Intervention: Caffeinated carbonated beverages (2 types)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-caffeinated carbonated beverages (2 types)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phosphoric acid without caffeine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water (neutral control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skim or chocolate milk (positive control)
Number of subjects: 0
Study: 9116952

Group type: EXPERIMENTAL
Intervention: Subdiaphragmatic instillation of bupivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 8343321

Group type: EXPERIMENTAL
Intervention: Transoesophageal atrial pacing (TAP)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Direct current cardioversion (DCC)
Number of subjects: 21
Study: 3759779

Group type: EXPERIMENTAL
Intervention: Biofeedback hyperventilation (to increase pH by 0.08‐0.10 at each work load)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Hyperventilation following acetazolamide (which returned pH to control values)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Metabolic acidosis induced by acetazolamide (with spontaneous ventilation)
Number of subjects: 8
Study: 30846617

Group type: EXPERIMENTAL
Intervention: Maternal gratitude
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Expert gratitude
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Combined maternal and expert gratitude
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (neutral statements)
Number of subjects: 43
Study: 28646977

Group type: EXPERIMENTAL
Intervention: Conjoint Behavioral Consultation (CBC)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 267
Study: 25453443

Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 1713

Group type: COMPARATOR
Intervention: Endarterectomy
Number of subjects: 1713

Group type: EXPERIMENTAL
Intervention: Stenting and Endarterectomy
Number of subjects: 1713
Study: 22990526

Group type: EXPERIMENTAL
Intervention: Hyperventilation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal ventilation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hypoventilation
Number of subjects: 30
Study: 22168267

Group type: EXPERIMENTAL
Intervention: PLUS (3‐month mobile phone and pedometer based physical activity intervention and 6‐month mobile phone diary maintenance intervention)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: REGULAR (3‐month mobile phone and pedometer based physical activity intervention and 6‐month pedometer maintenance intervention)
Number of subjects: 192

Group type: COMPARATOR
Intervention: CONTROL (pedometer only, but no intervention will be conducted)
Number of subjects: 192
Study: 20391859

Group type: EXPERIMENTAL
Intervention: Direct person‐to‐person prayer intervention (six weekly 1-hour sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no prayer sessions)
Number of subjects: 0
Study: 16968235

Group type: EXPERIMENTAL
Intervention: HSV‐1 shedding during the vesicle/ulcer stage
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HSV‐1 shedding during clinical stage
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HSV‐1 shedding during subclinical stage
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mean duration of HSV‐1 shedding
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall detection of HSV‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Average log DNA copy number/ml during clinical stage
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Average log DNA copy number/ml during subclinical stage
Number of subjects: 30
Study: 14717059

Group type: EXPERIMENTAL
Intervention: Mediterranean diet high in monounsaturated fat
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Carbohydrate‐rich diet
Number of subjects: 34

Group type: COMPARATOR
Intervention: Saturated fat diet
Number of subjects: 34
Study: 11020685

Group type: EXPERIMENTAL
Intervention: Endotracheal intubation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bag-valve-mask ventilation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training on paramedic airway management skills
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Costs of training and retraining
Number of subjects: 0
Study: 8801151

Group type: EXPERIMENTAL
Intervention: Prostaglandin F2 alpha (20 mg in 20 ml normal saline)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oxytocin (30 IU in 20 ml normal saline)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal saline (20 ml)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Manual removal of retained placenta (control group)
Number of subjects: 28
Study: 1325772

Group type: EXPERIMENTAL
Intervention: alpha h‐ANP (99‐126), 25 micrograms intravenously followed by infusion of 0.1 microgram kg‐1 min‐1
Number of subjects: 8

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 8
Study: 6095372

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus misonidazole (MIS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 62
Study: 31600368

Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 236

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 236
Study: 30497132

Group type: EXPERIMENTAL
Intervention: Depomedrol (DEPO) - 1 ml (80 mg) applied directly to the surgical site
Number of subjects: 93

Group type: COMPARATOR
Intervention: No Depomedrol (NODEPO) - 1 ml saline on Gelfoam carrier
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Depomedrol (DEPO)
Number of subjects: 93

Group type: COMPARATOR
Intervention: No Depomedrol (NODEPO)
Number of subjects: 93
Study: 25958237

Group type: EXPERIMENTAL
Intervention: COMPAS
Number of subjects: 1563

Group type: EXPERIMENTAL
Intervention: ¡Cuídate!
Number of subjects: 1563

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1563
Study: 24758565

Group type: EXPERIMENTAL
Intervention: DIMS0150 (30 mg rectal administration)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: DIMS0150
Number of subjects: 34
Study: 22487805

Group type: EXPERIMENTAL
Intervention: Awake flexible fiberoptic intubation (FFI)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Awake McGrath® video laryngoscope (MVL)
Number of subjects: 93